News Articles

September 22, 2022 – A Phase II Study of Domvanalimab and Zimberelimab Immunotherapy with or without FOLFOX Chemotherapy in People with Esophageal, Gastroesophageal Junction, or Stomach Cancer

The purpose of this study is to assess the safety and effectiveness of the investigational drugs domvanalimab and zimberelimab given together with or without FOLFOX chemotherapy in people with inoperable or metastatic upper digestive cancers. Both domvanalimab and zimberelimab take the brakes off the immune response by blocking certain proteins, enabling the immune system to find and destroy cancer cells. FOLFOX is a combination of chemotherapy drugs which is commonly used to treat digestive cancers.

Read more>

September 19, 2022 – Minimally Invasive Robotic and Laparoscopic Gastrectomy: A new ray of hope for gastric cancer

The stomach is a muscular J-shaped sac-like structure, mainly acts as reservoir for the food, located in the upper and left part of the abdomen and a crucial part of the Digestive organ of gastrointestinal system. It produces enzymes (Substances that create chemical reactions) and acids (digestive juices). This mix of enzymes and digestive juices breaks down food so it can pass to our small intestine(duodenum).

Read more> 

September 18, 2022 – First signs of esophageal cancer: You can recognize it early on with these warning signs

Die esophagus belongs to gastrointestinal tract and transports food from the throat to the stomach. Cancer of the esophagus is comparatively rare in Germany: men are four to five times more likely than women. The median age at diagnosis is 67 for men and 71 for women. The insidious thing about the disease: Symptoms usually appear very late. In many cases, patients only see a doctor at an advanced stage – for example because of difficulty swallowing. Therefore you should know the main symptoms of the esophageal cancer know. You might also be interested in: Deadly tumors – the most life-threatening cancer diseases.

Read more>

September 9, 2022 – ASCO: Amgen’s Stomach Cancer Drug, Nabbed in Five Prime Buyouts, Extends Patients’ Lives in Phase 2

Amgen battled other biopharma suitors for Five Prime Therapeutics early this year, emerging victorious in March with a $1.9 billion deal to snap up the cancer-focused biotech. Now, the company is painting a fuller picture for bemarituzumab, the crown jewel of the buyout, showing the treatment helped patients with advanced stomach cancer live longer.

Read more >>

September 1, 2022 – Grant Supports Research to Study Gastric Cancer Origins

Two Vanderbilt-Ingram Cancer Center researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level.

>>Read More

April 28, 2022 – Zymeworks Reports Last Patient Enrolled In Pivotal Study Of Zanidatamab In Treatment Of HER2-Expressing Late-Line Biliary Tract Cancer

VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Apr. 28, 2022– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activity of zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancers (BTC), including gallbladder cancer and cholangiocarcinoma (bile duct cancer). Efficacy and safety results from HERIZON-BTC-01 are expected to be announced by early 2023.

Read More>

November 9, 2021 – Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

VANCOUVER, British Columbia–(BUSINESS WIRE)–Nov. 9, 2021– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, together with its partner BeiGene, the launch of HERIZON‑GEA‑01. This is a randomized, global Phase 3 study evaluating Zymeworks’ investigational HER2‑targeted bispecific antibody, zanidatamab, plus chemotherapy, with or without BeiGene’s anti-PD‑1‑targeted antibody tislelizumab, versus standard of care (trastuzumab plus chemotherapy), for the first-line treatment of metastatic HER2‑postive GEA.

Read More>

November 1, 2021 – Taiho Press Release: Taiho Oncology Joins with Advocacy Partners to Underscore the Role of Proper Nutrition for Patients with Stomach Cancer During the Holiday Season and Beyond

November is a month associated with expressions of gratitude. We celebrate that which we are grateful for
with family and friends, often over a holiday meal. But, while many of us will express gratitude for our health, others are struggling with theirs and may not be able to fully participate in those gatherings because they, or a loved one, have been diagnosed with stomach cancer.

November is Stomach Cancer Awareness Month, and Taiho Oncology, Inc. is once again helping lead efforts to improve education and awareness, including nutritional awareness, for patients and families impacted by this disease.

Read More > 

October 21, 2021 – Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.

Read More > 

September 27, 2021 – U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo® (nivolumab) in combination with Yervoy (ipilimumab) and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), based on results from the CheckMate -648 trial. The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 28, 2022.

Read more >